Management of Antipsychotic-Induced Extrapyramidal Symptoms

Introduction to EPS Management

The American Academy of Child and Adolescent Psychiatry recommends immediate administration of benztropine 1-2 mg IM/IV or diphenhydramine 12.5-25 mg IM/IV for acute dystonia, providing relief within minutes 1, 2
For drug-induced parkinsonism, the first step is to reduce the antipsychotic dose, then switch to a lower-risk atypical antipsychotic (olanzapine, quetiapine, or clozapine) before adding anticholinergics 1, 2
Akathisia management involves reducing the antipsychotic dose first, then trialing a lipophilic beta-blocker (propranolol or metoprolol) as these are most effective 1, 2

Immediate pharmacological intervention is required for acute dystonia as it can be life-threatening, particularly with laryngospasm 1, 3
Administer benztropine 1-2 mg IM/IV immediately for rapid relief, with improvement often noticeable within minutes 1, 2, 3
Alternative: diphenhydramine 12.5-25 mg IM/IV provides equivalent rapid relief for acute dystonic reactions 2, 3

The treatment hierarchy prioritizes dose reduction and medication switching over adding anticholinergics 1, 2
Reduce the antipsychotic dose as the first strategy if clinically feasible 1, 2
Switch to olanzapine, quetiapine, or clozapine as the second-line strategy, as these have substantially lower EPS risk 2
Early diagnosis and rapid antipsychotic withdrawal improves the possibility of complete recovery from drug-induced parkinsonism 4

Akathisia is the most difficult EPS to treat and is frequently misinterpreted as psychotic agitation or anxiety, leading to inappropriate dose escalation 1, 2
Lower the antipsychotic dose if clinically feasible as the primary intervention 1, 2
Lipophilic beta-blockers, especially propranolol and metoprolol, are the most effective treatments for akathisia 1, 2

Olanzapine, quetiapine, and clozapine have the lowest EPS risk among atypical antipsychotics 2
Risperidone carries dose-dependent EPS risk that increases significantly above 2 mg/day in elderly/dementia patients and above 4-6 mg/day in general populations 2
Haloperidol and other high-potency agents produce significantly more EPS due to strong dopamine D2 receptor blockade 1, 2

Children and adolescents are at higher risk for EPS than adults, particularly acute dystonia in young males 1, 4, 3
Use particularly cautious dosing in pediatric populations despite some studies showing comparable EPS rates to placebo in controlled trials 2
Young males represent the highest-risk group for acute dystonia, typically occurring within the first few days of treatment 1, 2, 3

Regular monitoring for early EPS signs is the preferred prevention strategy rather than prophylactic anticholinergics 2
Monitor for tardive dyskinesia every 3-6 months using a standardized scale during long-term antipsychotic therapy 2
Tardive dyskinesia occurs in approximately 5% of young patients per year and is more common with typical antipsychotics 4

Anticholinergics can cause delirium, drowsiness, and paradoxical agitation, particularly in older adults 2
Exercise extreme caution in elderly patients due to oversedation, confusion, and paradoxical agitation risk 2
Avoid diphenhydramine in patients with glaucoma, benign prostatic hypertrophy, ischemic heart disease, or hypertension 2
Anticholinergics can paradoxically exacerbate agitation in patients with anticholinergic or sympathomimetic drug ingestions 2